Abstract Inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal tumors initially described in the lung. About half of them exhibit expression of the ALK1 protein, generally resulting from a gene rearrangement. Paranasal sinus IMTs are extremely uncommon, and gene rearrangement of ALK1 is very rare in this localization. A 47-year-old woman presented with rapidly progressive vision loss in her left eye. Clinical and imaging work-up revealed a tumor invading the left ethmoidal and sphenoidal sinuses and extending into the nasal cavity, the orbit and the skull base. Complete tumor resection was performed using an endonasal approach. Pathological examination revealed a paranasal localization of IMT, positive for ALK1 immunostaining. FISH analysis showed an ALK1 gene rearrangement. This case illustrates the local aggressive potential for IMTs. Treatment is primarily surgical, but targeted therapies (crizotinib) might be a solution for ALK1 rearranged cases with a poor prognosis.
Introduction
Inflammatory myofibroblastic tumors (IMTs) are rare soft tissue tumors, which have primarily been described in the lungs. Extra-pulmonary IMTs occur throughout the body. Approximately 10 % of these involve the upper aerodigestive tract, primarily the larynx. Between 36 and 60 % of IMTs show an immunoreactivity for the Anaplastic Lymphoma Kinase 1 (ALK1) antibody [1] . This over expression may be caused by different molecular abnormalities, most frequently by a gene rearrangement [1] , but it may involve other molecular events.
The present study reports a case of paranasal sinus IMT with an ALK1 gene rearrangement. The patient provided informed consent for the use of her clinical data. To the best of our knowledge, this is the second case described in the literature of paranasal sinus IMT displaying an immunoreactivity for the ALK1 antibody, caused by an ALK1 gene rearrangement confirmed by FISH. Clinical, radiological and pathological findings of the tumor are described, and a review was carried out.
Case Description
A 47-year-old woman presented with a left-sided nasal obstruction associated with rapidly progressive left-sided visual loss. She complained of a long-lasting nasal obstruction before her left vision was compromised. She reported no medical history, no smoking or alcohol use, and no family history. The initial clinical examination revealed a large mass filling the entire left nasal cavity, which was responsible for a septal deviation. Ocular motility was normal, but the left visual acuity was 4/20 with a paracentral left temporal scotoma. There were no other neurologic deficits.
A head computed tomography (CT) scan revealed a lesion occupying the entire left ethmoid sinus extending to the contralateral ethmoid, with lysis of the skull base and lamina papyracea, without obvious crossing of the left periorbit. The lesion also extended to the left nasal cavity and sphenoid sinus (Fig. 1) . Magnetic resonance imaging (MRI) revealed a homogeneous tumor showing an isointense signal in T1-weighted images and a hyperintensity in T2-weighted images, with intense and homogeneous enhancement after contrast injection. The optic nerve was not followed on MRI, and the lesion was in contact with the internal carotid artery (Fig. 2) .
Biopsies under local anesthesia were carried out, and an inflammatory myofibroblastic tumor was diagnosed. The patient underwent a semi-emergency surgery to prevent visual loss. Complete tumor resection was performed using an endonasal approach with bilateral ethmoidectomy, bilateral sphenoidectomy, access to the left cavernous sinus and dissection of the optic nerve and the internal carotid artery, which were dehiscent, and a type II nasopharyngectomy [2] . Excision showed a hemorrhagic tumor, which was mainly implanted in the left sphenoid sinus and along the left orbit.
On day one after surgery, the visual acuity of the patient recovered with persistence of a small central scotoma. A postoperative MRI showed complete resection. Control imaging 1 year after surgery (Fig. 3) showed a non-specific contrast enhancement in the right sphenoid, while a systematic biopsy was negative for tumor.
Microscopic examination of the biopsy and subsequent surgical specimen (Fig. 4) showed a spindle cell proliferation, dispersed in an abundant edematous myxoïd inflammatory stroma infiltrated by numerous lymphocytes, plasma cells and eosinophils. Vascularization was abundant with no typical hemangiopericytic feature.
Immunohistochemical analysis revealed diffuse cytoplasmic reactivity for ALK1 (Fig. 5a ); AE1 and AE3 keratins were weakly and very focally expressed (Fig. 5b) . There was no expression of smooth muscle actin (Fig. 5c ), CK5/ 6, CD34 or desmin. Tumor cells showed a cytoplasmic but no nuclear expression of beta catenin, and S100 protein was weakly expressed in the cytoplasm of rare tumor cells (Fig. 5d ). Mitoses were scarce, but many atypia were present, and the proliferation index was high, up to 30 % in the hot-spots. Using ALK break-apart FISH, most tumor cells displayed one colocalization signal (indicating a normal ALK allele) and a split signal (indicating a rearranged ALK allele). The spacing of the split signals was large, indicating an ALK rearrangement through a translocation rather than an inversion (Fig. 6 ).
Discussion
Inflammatory myofibroblastic tumors are solid mesenchymal tumors that were first described in the lung by Pettinato [3] . IMTs have since been reported in numerous extrapulmonary sites, including the abdomen, pelvis, urogenital system, orbit, oral cavity, and nose and paranasal sinuses. These are usually benign tumors, with local development, but malignant behavior with metastasis is described in 5 % of cases [4] . Recurrences may occur in 25 % of cases depending on completeness of surgical resection [4] . Microscopic examination reveals a proliferation of differentiated myofibroblastic spindle cells associated with an infiltrate of inflammatory cells (lymphocytes and plasma cells) in variable myxoid or collagen stroma. Coffin et al. [5] described three main histopathological subtypes: He et al. [6] were the first to show that the (a) and (b) patterns were associated with poor event-free-survival in the nasal and paranasal sinuses. Malignancy is histologically suspected in cellular cases with nuclear atypia, high proliferation index, high cellularity, necrosis, and ganglion-like cells [6] . The pathogenesis of IMT is unclear. Based on the presence of infectious agents described in some IMTs, several authors have hypothesized that there is an initial infectious process that triggers an inappropriate inflammatory response and reactive myofibroblastic proliferation [7, 8] . The causative germs vary and could be bacteria, virus or fungus.
IMTs of the head and neck are predominantly located in the larynx, orbit, oral cavity and paranasal sinuses, with no age or sex predilection. IMTs of the nose and paranasal sinuses are rare. Mainly case reports, and one case series, are available in the literature. Table 1 describes the main features of these tumors [6, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
Clinically, a non-specific nasal tumor syndrome gradually develops with unilateral nasal obstruction, facial pain, and epistaxis. Less frequently, the tumor is revealed by cranial nerve palsy, facial edema, hyposmia, or proptosis. Unlike in other locations, systemic inflammatory anomalies (fever, weight loss, anemia, hyper-gammaglobulinemia, and ESR and CRP increase) are rare in the head and neck. The imaging (CT scan and MRI) shows a homogeneous strongly enhancing tumor after injection of contrast. The CT scan reveals a mass syndrome with bone lysis and sometimes demonstrates calcifications in the tumor [14] .
The treatment of these tumors relies on surgical excision with the goal of complete resection. Some authors have reported treatment with external radiation. In the series of Lee et al. [19] , 6 patients with skull base IMTs received small dose radiation (20 Gy) with no effect, while Sasagawa et al. [20] report local control after 20 Gy radiation. In the cases of paranasal sinus IMTs reported in the literature (Table 1) , one patient relapsed after treatment with 40 Gy radiation [10] , and a second is currently in complete remission 2 years after the end of treatment with 20 Gy radiation [13] . As reported in the literature, 20 out of 37 patients who underwent surgery for paranasal sinus IMTs experienced tumor recurrence, two cases showed metastatic evolution [6, 14] , and 6 patients died of the tumor [6, 14] . Necrosis, a high proliferation index, the presence of ganglion-like cells, and more than four relapses were shown to be poor prognostic factors [6] . The IMTs belong to a group of myofibroblastic tumors that include many subtypes [21] . In the paranasal sinuses, the best known is nasopharyngeal angiofibroma. Table 2 describes the typical features of myofibroblastic tumors in these locations.
Our case is the second paranasal sinus IMT with ALK1 immunohistochemical expression described in the literature. There appears to be a good correlation between immunohistochemical expression of ALK1 and molecular abnormalities [1] . In our case, the ALK1 gene rearrangement was confirmed by FISH analysis. The Anaplastic Lymphoma Kinase 1 (ALK1) gene encodes a tyrosine kinase receptor that belongs to the insulin receptor family, which is normally present in a few neuronal cells. Its expression is most frequently caused by a rearrangement of the ALK1 gene (on the short arm of chromosome 2 in the p21-p23 region) with different possible partners. The fusion product is responsible for ALK1 protein overexpression. It was first described in anaplastic large cell lymphoma, with a favorable prognosis [22] .
Griffin et al. [23] first suggested that the recurrent translocation seen in inflammatory IMTs could involve ALK. The literature reports that between 9 and 63 % of IMTs have a mutation activating the ALK1 receptor [24] . The presence of this mutation confirms the neoplastic nature of this lesion. No obvious link is reported between ALK1 rearrangement and the inappropriate inflammatory response hypothesis in IMT. According to Coffin [24] and Chan [25] , tumors expressing the mutation tend to occur in younger patients (under 40 years of age). ALK1 expression may impact the presentation and prognosis of IMTs: ALK1-positive IMTs seem to present a higher risk of local recurrence than ALK1-negative IMTs [24, 25] . Only one metastatic case with an ALK1 rearrangement is reported in the literature [26] . ALK1-positive IMTs seem to show more atypia and less mitosis [25] . Our case supports this finding; there was no noticeable mitotic activity, but marked atypia and a proliferation index up to 30 % was observed in the hot-spots.
Expression of ALK1 paves the way for personalized treatment and molecular-targeted therapy. While the therapeutic use of inhibitors of tyrosine kinases is being tested for ALK1 rearranged neuroblastoma, glioblastoma, lung cancer and breast cancer [27] , there are some recent reports concerning the use of targeted therapies for IMTs. Crizotinib (an inhibitor of ALK tyrosine kinase) was tested in one patient with ALK1-positive IMT by Butrynski et al. [28] . He responded to treatment, with a reduction of more than 50 % of the tumor volume. More recently, a complete remission was obtained with crizotinib in a patient with metastatic ALK1-positive IMT [26] . In the case of deepseated lesions, crizotinib should therefore be considered as a therapeutic option for recurrent tumors.
As shown by the case reported here, at least some sinonasal IMTs are related to ALK1 gene rearrangement, as demonstrated by immunohistochemical expression of the ALK protein and signal split in the FISH analysis. Although complete surgical resection seems to be the best treatment for these tumors when possible, targeted therapies with tyrosine kinase inhibitors may represent an alternative solution for ALK1 large or recurring tumors, which are not amenable for surgery.
